Dr. Chantal J.M. van Opbergen is a postdoctoral research fellow whose work centers on uncovering the molecular and cellular mechanisms underlying arrhythmogenic cardiomyopathy (ARVC) and mechanisms of cardiac arrhythmias in other inherited cardiomyopathies. She earned her PhD from Utrecht University (2020) by investigating calcium-sensitive pathways in ARVC, and subsequently continued her research at New York University School of Medicine (2019) and Amsterdam UMC (2023). Here, she focuses on multidisciplinary projects that bridge preclinical discovery with translational applications; including a gene therapy approach for PKP2-ARVC resulting in a Phase 1 FDA-approved clinical trial.
